Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Clinical trials sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., explained in plain language.
-
New combo therapy targets tough lymphoma
Disease control Recruiting nowThis study tests a new drug called TQB2825 combined with standard immunochemotherapy for people with diffuse large B-cell lymphoma (DLBCL), either newly diagnosed or relapsed. The goal is to see if the combination improves tumor shrinkage and controls the disease longer. About 90…
Phase: PHASE1, PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Apr 29, 2026 00:50 UTC
-
New injection aims to tame stubborn sinusitis for good
Disease control Recruiting nowThis study tests a new drug called TQH2722 for people with severe chronic sinusitis, with or without nasal polyps. The goal is to see if it is safe and works well over a long period. About 120 adults who have already been in a related study will receive one of two doses and be mo…
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Apr 29, 2026 00:50 UTC
-
New hope for tough thyroid cancers: drug trial aims to slow tumor growth
Disease control Recruiting nowThis study tests a new drug called AL2846 in people with advanced thyroid cancer that no longer responds to radioactive iodine or previous targeted therapy. The goal is to see if the drug can delay cancer growth compared to a placebo. About 144 participants will take either AL284…
Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Apr 29, 2026 00:49 UTC
-
New pill TQB3205 enters human testing for advanced cancers
Disease control Recruiting nowThis early-phase study tests a new oral drug, TQB3205, in 156 adults with advanced malignant tumors that have not responded to other treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for early signs that the drug shrinks tum…
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC
-
Liver Function's impact on new myelofibrosis drug tested
Knowledge-focused Recruiting nowThis early-stage study looks at how the drug TQ05105 behaves in people with mild or moderate liver impairment compared to healthy volunteers. About 24 participants will receive a single dose to measure drug levels and check for side effects. The goal is to understand if liver fun…
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Knowledge-focused
Last updated Apr 29, 2026 00:51 UTC